Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Scalori

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Hepatology (Baltimore, Md.)|February 15, 2001
Psychological screening before interferon therapyA Scalori, P Apale, L Roffi
The American Journal of Gastroenterology|October 1, 1996
Breakthrough of interferon therapyA Scalori, A Ricci, G Bellati, et al.
European Journal of Gastroenterology & Hepatology|June 1, 2000
Depression during interferon therapy for chronic viral hepatitis: early identification of patients at risk by means of a computerized testA Scalori, P Apale, F Panizzuti, et al.
The American Journal of Gastroenterology|September 11, 1998
HCV genotypes and breakthrough in patients treated with recombinant alpha interferonL Roffi, G Colloredo, B Brugnetti, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 1, 2005
Interferon-induced depression: prevalence and managementA Scalori, M Pozzi, V Bellia, et al.
Journal of Viral Hepatitis|December 22, 1999
Prediction of relapse or sustained response in biochemical responders by serum hepatitis C virus RNA monitoring during interferon therapyG Colloredo, L Roffi, M R Brunetto, et al.
European Journal of Gastroenterology & Hepatology|June 9, 2001
Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotypeL Roffi, A Redaelli, G Colloredo, et al.
Journal of Hepatology|December 2, 1998
HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patientsL Roffi, A Ricci, C Ogliari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX studyS Peters, R Camidge, R Dziadziuszko, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Hepatology (Baltimore, Md.)|February 15, 2001
Psychological screening before interferon therapyA Scalori, P Apale, L Roffi
The American Journal of Gastroenterology|October 1, 1996
Breakthrough of interferon therapyA Scalori, A Ricci, G Bellati, et al.
European Journal of Gastroenterology & Hepatology|June 1, 2000
Depression during interferon therapy for chronic viral hepatitis: early identification of patients at risk by means of a computerized testA Scalori, P Apale, F Panizzuti, et al.
The American Journal of Gastroenterology|September 11, 1998
HCV genotypes and breakthrough in patients treated with recombinant alpha interferonL Roffi, G Colloredo, B Brugnetti, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|March 1, 2005
Interferon-induced depression: prevalence and managementA Scalori, M Pozzi, V Bellia, et al.
Journal of Viral Hepatitis|December 22, 1999
Prediction of relapse or sustained response in biochemical responders by serum hepatitis C virus RNA monitoring during interferon therapyG Colloredo, L Roffi, M R Brunetto, et al.
European Journal of Gastroenterology & Hepatology|June 9, 2001
Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotypeL Roffi, A Redaelli, G Colloredo, et al.
Journal of Hepatology|December 2, 1998
HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patientsL Roffi, A Ricci, C Ogliari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX studyS Peters, R Camidge, R Dziadziuszko, et al.
Pageof 1